Tag results:
STAT3
Hepatic Cell News
Therapeutic Effects of TM4SF5-Targeting Chimeric and Humanized Monoclonal Antibodies in Hepatocellular and Colon Cancer Models
[Molecular Therapy-Oncolytics] The authors evaluated the effects of chimeric Ab27 using cancer cells expressing endogenous transmembrane 4 L six family member 5 (TM4SF5) or stably overexpressing TM4SF5 in vivo and in vitro.
Pancreatic Cell News
The Inhibition of Panc1 Cancer Cells Invasion by hAMSCs Secretome through Suppression of Tyrosine Phosphorylation of SGK223 (at Y411 Site), C-src (at Y416, Y530...
[Medical Oncology] Researchers employed a co-culture system to clarify the effects of human amniotic mesenchymal stromal cells secretome through tyrosine phosphorylation of c-Src, SGK223, AKT activity, and JAK1/Stat3 signaling in Panc1 pancreatic cancer cells.
Dermal Cell News
TSLP Impairs Epidermal Barrier Integrity by Stimulating the Formation of Nuclear IL-33/Phosphorylated STAT3 Complex in Human Keratinocytes
[Journal of Investigative Dermatology] Researchers stimulated post-confluent human keratinocytes and living skin equivalent with TSLP to investigate the role of nuclear IL-33 in TSLP-induced epidermal barrier defects.
Mammary Cell News
STAT3 Induces Breast Cancer Growth via ANGPTL4, MMP13 and STC1 Secretion by Cancer Associated Fibroblasts
[Oncogene] Researchers demonstrated that STAT3 was essential for the pro-tumorigenic functions of murine breast cancer cancer associated fibroblasts both in vitro and in vivo, and identified a STAT3 signature significantly enriched for genes encoding for secreted proteins.
Hepatic Cell News
The E3 Ubiquitin Ligase SOCS-7 Reverses Immunosuppression via Shc1 Signaling in Hepatocellular Carcinoma
[Laboratory Investigation] Scientists identified SOCS-7, an inhibitor of cytokine signaling, as a novel regulator of immunosuppression in hepatocellular carcinoma.
Mesenchymal Cell News
miR-204–Containing Exosomes Ameliorate GVHD-Associated Dry Eye Disease
[Science Advances] Investigators reported that exosomes from MSCs administered as eye drops notably alleviated graft-versus-host disease-associated dry eye disease by suppressing inflammation and improving epithelial recovery in mice and humans.